Cardiogoniometry in psoriatic patients and its comparison with a control group

Hoorak Poorzand a, Bita Kiafar b,*, Fardideh Asadzadeh Heravi a, Mohammad Vejdanparast a, Azadeh Saki c, Mohammad Tayebi a, Negar Morovatdar d, Neda Karimabadia a

a Atherosclerosis Prevention Research Center, Cardiovascular Department, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
b Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
c Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
d Imam Reza Clinical Research Unit, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

What is already known?
• Increased incidence of coronary artery or myocardial involvement and defects in automatic setting of heart activity have been reported in psoriasis which could be related to the presence of systemic inflammation.

What this study adds
• Cardiologic examination is an important work up in psoriatic patients especially cases with severe skin involvement. There are no data regarding cardiogoniometry in psoriasis patients. CGM is a method, which could provide additive data using SDNN (as a marker for heart rate variability) and also myocardial ischemia score.

1. Introduction
Psoriasis is a common T cell mediated inflammatory and chronic disease affecting almost 1–3% of the human population.1
It is characterized by hyper proliferation and loss of normal differentiation in the epidermis, vascular changes, and lymphocytic infiltration.

Although best known for its dermatologic manifestations, psoriasis may also accompany several other important morbidities, including: arthritis, cancer, Crohn’s disease, ulcerative colitis, non-alcoholic steatohepatitis, diabetes, depression, and cardiovascular abnormalities. Systemic inflammation in psoriasis is associated with many cardiovascular unfavorable changes including: endothelial dysfunction, hypertension, platelet adhesion, and heart rate variability. In a study by Ludwig et al. on psoriatic patients, increased risk of myocardial infarction was found even after controlling for coronary risk factors. This was more evident in those with severe diseases.

Patients with psoriasis have a shorter life expectancy, ascribed to be due to cardiovascular abnormalities in most cases. Considering these data, it seems to be prudent to diagnose earlier such cardiovascular abnormalities and manage them properly for improving the survival in Psoriasis.

Cardiogoniometry (CGM) is a spatio-temporal orthogonal-lead method using multiple electrodes and an automated diagnostic algorithm to analyze a 12 s vectorcardiographic recording in the resting patient. It detects variables that are helpful in identifying ischemic heart disease or predicting heart rate variability, being performed under resting conditions.

There are no data regarding cardiogoniometry in psoriasis patients. The aim of this study was to use ECG and CGM parameters as indicators of cardiovascular abnormalities in psoriatic patients and compare them with normal population.

2. Methods

Thirty patients, clinically diagnosed as psoriasis vulgaris by an academic dermatologist, were involved in this cross-sectional study from 2014 to 2015. They were selected consecutively from the patients visiting the dermatologic clinic (Imam Reza Hospital). The included patients did not have any clinical signs or symptoms of cardiac problems, history of heart diseases, neurologic events or conventional risk factors for atherosclerosis (hypertension, hyperlipidaemia, diabetes mellitus or cigarette smoking) or medications including beta blocker, systemic steroids or antiagulants. Thirty healthy volunteer subjects were also enrolled. They were the colleagues or family members of the study author or psoriasis patients and did not have the clinical evidence of cardiac or systemic disorders. Having similar age range and sex ratio to the patients visiting the dermatologic clinic (Imam Reza Hospital). The study data were collected by a commercial CGM device (Cardiologic Explorer, Enverdis GmbH Medical Solutions, Germany; Model E12X34). Four electrodes are placed at four points on the patient’s thorax as follows (Fig. 1): Electrode 1, at point V4 of Wilson (5th intercostal space in the mid-clavicular line); 2, at point V8 of Wilson (5th intercostal space in the scapular line); 3, located perpendicularly above electrode 1 at 0.7 times the distance between electrode 1 and 2; Electrode 4, to the right of electrode 3 at the same distance as between points 1 and 3. Vectorial addition of the three potentials between pairs of these electrodes results in a vector that describes the electric field in each plane (X, Y, Z).

During the recording, the patients lay in a supine position and were asked to hold their breath for 12–15 s after normal expiration. If this was not possible, they were asked to perform shallow breathing and keep their thoracic excursions to a minimum.

Cardiogoniometry uses different parameters compiled into specific sets based on gender and conduction characteristics. Analysis of all parameters is fully automated. Myocardial ischemia score is expressed as values ≤0 (Figs. 2 and 3). Another parameter, defined as standard deviation of normal R-R interval (SDNN), is used analogous to the extent of heart rate variability.

The CGM results were collected by an independent investigator blinded to all patient data.

2.2. Twelve-lead electrocardiography

The resting 12-lead ECG (Cardisuny C120, Fukuda, Japan) was recorded after the CGM. All ECGs were analyzed by one independent investigator blinded to all patient data. The QT interval was measured from the onset of the QRS complex to the end of the T wave.

Due to the differences in QT interval in the different leads, the maximum QT interval, measured manually, was used in each case. Corrected QT interval was measured using this formula:

\[
\text{QTc} = \frac{\text{QT}}{\text{HR}^{0.75}}
\]

\[
\text{QTc} = \text{QT} + 1.75(\text{HR} – 60)
\]

QT dispersion was defined as maximum difference in QT interval considering all leads.
Presence or absence of pathologic ST-T changes was evaluated in all electrocardiograms (e.g., ECG changes for myocardial ischemia or prior myocardial infarction). These criteria were defined as horizontal or down-sloping ST depression ≥0.05 mV in two contiguous leads; and/or T inversion ≥0.1 mV.

Serum level of magnesium, potassium and calcium were determined at the day of ECG analysis in all psoriatic patients.

2.3. Statistical analysis

All the statistical analyses were performed using the SPSS statistical software (Statistical Package for Social Sciences, version 16.0). Continuous variables were presented as means ± standard deviation (SD). Normality tests (Kolmogorov–Smirnov and Shapiro–Wilk) were used to assess the distribution pattern of variables. T-test and chi-square test were used for analysis of quantitative and qualitative variables, respectively. In case the data were not normally distributed, non-parametric tests were used for comparison. Pearson correlation analysis was used to assess the correlation between variables. Level of significance was set at 0.05.

3. Results

Thirty psoriatic patients (40% (n: 12) female, the mean age of 45.43 ± 12.42 years) and 30 healthy persons as control group (40% (n: 12) female, the mean age of 43.90 ± 12.79 years) participated. Both groups were matched by the age (p = 0.64) and the sex. Neither psoriatic patients nor control group had risk factors for cardiovascular diseases (including hypertension, hyperlipidaemia, diabetes mellitus, cigarette smoking or family history of cardiovascular disease). All psoriatic patients had normal sinus rhythm without ST-T changes. ECG parameters (QT interval and dispersion) and CGM variables (myocardial ischemia score and SDNN) were gathered in both groups.
Table 1
ECG and CGM related variables in normal and patient group.

| Variable                  | Patient group N=30 | Control group N=30 | p value |
|---------------------------|--------------------|--------------------|---------|
| QT interval               | 364.00 ± 18.495    | 355.33 ± 17.167    | 0.065   |
| QT corrected              | 392.64 ± 26.00     | 377.26 ± 22.34     | 0.017   |
| QT dispersion             | 32.00 ± 17.88      | 6.67 ± 15.162      | <0.001  |
| Heart rate                | 76.37 ± 14.41      | 72.53 ± 9.684      | 0.02    |
| SDNN                      | 36.37 ± 21.01      | 29.60 ± 14.88      | 0.29    |
| Myocardial ischemia score | -1.53 ± 2.63       | -0.46 ± 0.73       | 0.037   |

All variables are given as mean ± SD; SDNN: standard deviation of normal R-R interval.

(Table 1). The mean value of these parameters was shown as comparative bar charts (Figs. 4–6).

There was significant difference between the psoriasis patients and the controls in term of myocardial ischemia score (1.53 ± 2.63 vs 0.46 ± 0.73, p = 0.037). Thirty three percent of the controls had score <0 compared with 43% in the patient groups but the ranges were −2.0 in the controls compared to −8.0 in the patients (Figs. 6 and 7).

There was not significant correlation between QT interval and QT dispersion with PASI (r = 0.31, p = 0.873 and r = 0.213, p = 0.259), or between QT interval and disease duration (r = 0.051, p = 0.359). Moderate correlation was found between QT dispersion and the disease duration (r = 0.369, p = 0.022).

Heart rate showed positive correlation with PASI (r = 0.427; p = 0.009) but not with disease duration (p = 0.170; r = 0.180). SDNN and myocardial ischemia score had positive correlation with PASI (r = 0.427; p = 0.009, r = 0.481; p = 0.004) but not with the disease duration (r = 0.124; p = 0.257; r = 0.233; p = 0.108).

4. Discussion

Cardiogoniometry is a non-invasive cardiovascular diagnostic method, easy to use and inexpensive, providing automated interpretation. It was assumed to be useful for early diagnosis of ischemic heart disease especially in those patients who do not tolerate exercise testing. Support vector machines have been applied in this technique to increase the diagnostic accuracy (compared to the previous discriminant function analysis).

Resting ECG is not a precise screening method for detecting myocardial ischemia in the primary setting. On the other hand, exercise ECG often cannot be performed in all patients.

Vector cardiography (VCG) has been proposed as an alternative to the standard 12-lead ECG since the late 1930s.11 In VCG, spatial and temporal heterogeneity of the repolarization phase (named as T-wave variability and T-wave alternance) have been used for predicting ventricular tachyarrhythmia or sudden cardiac death.

But it never became widely used in routine clinical practice due to difficulty to interpret. On the other hand, coronary angiography and nuclear imaging methods caused the classic VCG being disappeared.

Cardiogoniometry had been presented by Sanz et al. as an alternative to classic VCG in ischemic heart disease diagnosis (IHD).12 CGM is a vectorcardiographic method that is easier to record than the conventional ECG (4 leads instead of 12), clearly displays accurate three-dimensional surface electrophysiological
information and provides automated diagnostic evaluation of digitalized measurements. The variables used in the CGM score serve to identify the abnormal spatial localization of cardiac potentials and abnormal beat-to-beat variability. The use of these variables is plausible since alterations of repolarization and depolarization potentials are commonly used in the ECG diagnosis of IHD.\textsuperscript{14,15}

In a study on psoriatic patient without history of heart disease, heart rate was significantly higher (day and night) than the control group using Holter monitoring. We did not use ECG Holter monitoring in our study. The heart rate in ECG was higher compared with the controls, showing positive correlation with PASI but not with the disease duration.\textsuperscript{16}

QT dispersion (QTd) can be used to assess the homogeneity of cardiac repolarization and autonomic function denoting the increased heterogeneity of repolarization could be associated with increased risk of ventricular tachyarrhythmias.\textsuperscript{17,18}

QT interval and QTD was higher in psoriatic patients, which could be suggestive for increased risk of arrhythmia in such group (like the study by Simsek at al). There was also positive correlation between disease duration and QTD, which was moderate in our study ($r = 0.369; p = 0.022$), compared with Simsek et al. study who found significant relation ($r = 0.693; p < 0.001$). There were not significant correlations between PASI and QT dispersion.$^{19}$

The data on rhythm disturbances or conduction abnormalities are scarce. Increased sympathetic activity or systemic inflammation has been proposed as the mechanism of increased QT.\textsuperscript{20}

We did not include the inflammatory markers in this study. PASI score reflects the disease severity, thus it could also be regarded as a useful measure of systemic inflammatory processes intensity. Positive correlation was found between SDNN and PASI but not with QT dispersion in our study. This might suggest the inflammatory mechanism for increased heart rate variability in such patients.

The association of psoriasis with comorbidities increasing the risk of cardiovascular diseases was highlighted in many studies and psoriasis was also found to be independently related with myocardial infarction.\textsuperscript{21–23} Psoriasis has been associated with an increased risk of atherosclerosis (e.g., ischemic heart disease and stroke). The prevalence of such risk factors seems to increase from mild to severe cases.\textsuperscript{24}

In a meta-analysis, CGM was accurate in detecting $\geq50\%$ coronary artery stenosis at rest with a sensitivity of 73\% and a specificity of 84\%, respectively.\textsuperscript{25}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig6.png}
\caption{Fig. 6. Bar charts comparing the mean value of myocardial ischemia score in the patients and controls, the error bars have been superimposed.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig7.png}
\caption{Fig. 7. Distribution of myocardial ischemia score in frequency in the patients and controls.}
\end{figure}
In study by Schupbacha et al., CGM showed a higher sensitivity but similar specificity of for detecting CAD compared with ECG.26

In this study, there were no ST T changes in resting electrocardiogram but more negative values for myocardial ischemic score were noted in CGM in psoriatic patients. The main concern was that a confirmatory test for coronary artery disease (CAD) was not done, so the extent of atherosclerotic burden could not be evaluated and the differences found in ischemia score could not be simply ascribed to CAD. On the other hand, scores <0 was also detected in the controls which raised the suspicion for generalized applicability of CGM for myocardial ischemia detection in psoriasis.

After all, the abnormalities detected by CGM would raise concerns about further cardiovascular follow-up in psoriatic patients at least in those with severe disease. In other words, it is prudent to define the risk of cardiovascular disease in psoriasis and understand its determinants to propose the effective prevention strategies.

5. Conclusion

Cardiogoniometry is a new, noninvasive, quantitative electro diagnostic technique, which is helpful in identifying patients with cardiovascular abnormalities and also predicting heart rate variability. It can easily be performed at rest and provides an accurate, automated diagnostic score. Abnormalities in resting ECG and CGM and their positive relation with disease severity could raise concerns about further cardiovascular follow-up in psoriatic patients at least in those with severe disease. Whether increased QTd and abnormalities in CGM parameters in patients with psoriasis predicts poorer clinical outcomes or mandates any special treatments warrants further study.

5.1. Limitations

Small number of study patients and lack of long-term clinical follow-up are the major limitations of our study. CT coronary angiography or conventional angiography was not done. The extent of atherosclerotic burden and the clinical importance of the differences found in CGM data could not be defined. Serum markers of inflammation were not measured, so the exact pathophysiologic mechanism of cardiovascular abnormalities could not be evaluated. Automated ECG measurements were not available and manual calculation QT measurements may be criticized.

Conflicts of interest

The authors have none to declare.

Acknowledgement

This work was derived from a student thesis (thesis number: 7138), and supported by a grant from the Research Council of Mashhad University of Medical Sciences.

References

1. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:11–18.
2. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011;146:9–15.
3. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation Clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031–1042.
4. Wakkée M, Thio HB, Preus EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1–9.
5. Pietraik A, Bartosińska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol. 2013;52:153–162.
6. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271–276.
7. Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol. 2013;44:194–204.
8. Seeck A, Garde A, Schuepbach M. Diagnosis of ischemic heart disease with cardiogoniometry-linear discriminant analysis versus support vector machines. In: Vander Sloten J, Verdonck P, Marc Nyssen M, eds. et al: IFMBE Proceedings. Berlin: Springer; 2009.
9. Ashcroft DM, Wan Po AT, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141:185–191.
10. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiography. J Am Coll Cardiol. 2009;53:982–991.
11. Birkemeyer R, Toegl R, Zeymer U, et al. Comparison of cardiogoniometry and electrocardiography with perfusion cardiac magnetic resonance imaging and late gadolinium enhancement. Europace. 2012;14:1793–1798.
12. Wilson FN, Johnston FD. The vector cardiogram. Am Heart J. 1938;16:14–28.
13. Sanz E, Steiger JP, Thie W. Cardiogoniometry. Clin Cardiol. 1983;6:199–206.
14. Fayn J, Rubel P, Pahlm O, Wagner GS. Improvement of the detection of myocardial ischemia thanks to information technologies. Int J Cardiol. 2007;120:172–180.
15. Zabel M, Malik M. Practical use of T wave morphology assessment. Cardiac Electrophysiol Rev. 2002;6:316–322.
16. Markuszeski L, Bissinger A, Januszi L, Narbutt J, Jędrezejowa AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res. 2007;38:64–69.
17. Kautzner J, Malik M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol. 1997;20(10 Pt 2):2625–2640.
18. Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol. 1995;25:746–752.
19. Simsek H, Sahin M, Akoly A, et al. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. Sci World J. 2013;2013:901215.
20. Marfella R, Caltabiano P, Siniscalchi M, et al. Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. Hypertension. 2003;41:237–243.
21. Horreau C, Poulard C, Brena E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(suppl 3):12–29.
22. Pancar Yuksel E, Yuksel S, Yenercag M, et al. Impaired heart rate recovery indices in psoriasis patients. Med Sci Monit. 2014;20:350–354.
23. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–307.
24. Siegel D, Devaraj S, Mitra A, et al. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol. 2013;44:194–204.
25. Huebner T, Goernig M, Schuepbach M, et al. Electrocardiographic and related methods of non-invasive detection and risk stratification in myocardial ischemia: state of the art and perspectives. Ger Med Sci. 2010;8(October). Doc27.
26. Schupbacha WM, Ernese B, Loretan P, et al. Non-invasive diagnosis of coronary artery disease using cardiogoniometry performed at rest. Swiss Med Wkly. 2008;138(15–16):230–238.